Radiation plus immunotherapy and chemotherapy for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery.
- You have at least one tumor that can be measured on scans (like a CT or MRI).
- You are in good enough health to carry out daily activities (ECOG score 0-1).
- You have not received immunotherapy (like PD-1 or PD-L1 inhibitors) or chemotherapy for bile duct cancer before.
- Your blood counts and organ function (liver, kidneys, blood clotting) are within acceptable ranges per standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.